Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Submit a comment

Development of Cellular and Humoral Immunity in the Respiratory Tract of Rabbits to Pseudomonas Lipopolysaccharide
Herbert Y. Reynolds, … , Russell E. Thompson, Henry B. Devlin
Herbert Y. Reynolds, … , Russell E. Thompson, Henry B. Devlin
Published May 1, 1974
Citation Information: J Clin Invest. 1974;53(5):1351-1358. https://doi.org/10.1172/JCI107683.
View: Text | PDF
Research Article

Development of Cellular and Humoral Immunity in the Respiratory Tract of Rabbits to Pseudomonas Lipopolysaccharide

  • Text
  • PDF
Abstract

Immunization with Pseudomonas lipopolysaccharide induced both cellular and humoral immunity in rabbits, particularly in the respiratory tract after intranasal immunization. Either parenteral (i.m.) or intranasal immunization elicited an IgG antibody response in respiratory secretions, but only intranasal immunization produced secretory IgA antibody. Immunization by both routes stimulated serum IgM and IgG agglutinative antibodies. Because both methods of immunization produced skin test reactivity which had components of both Arthus and tuberculin-like reactions, cellular immunity was more readily assessed by the measurement of migration inhibitory factor (MIF) released from immune lymphocytes in respiratory and spleen cell suspensions after challenge with the lipopolysaccharide antigen. After intranasal vaccination, MIF activity was detected in the respiratory tract by direct assay; in contrast, i.m. immunized rabbits did not produce respiratory MIF. Both modes of immunization resulted in splenic MIF activity. However, lymphocytes were only capable of producing MIF for short periods after primary immunization had ended, apparently losing this function in about 2-3 wk. Therefore, it was concluded that cellular immunity by in vitro assay was transient after primary immunization with this Pseudomonas antigen in contrast to the more persistent humoral immunity. The biological significance of immune lymphocytes as part of the coordinated host defense of the lung needs further evaluation.

Authors

Herbert Y. Reynolds, Russell E. Thompson, Henry B. Devlin

×

Guidelines

The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.

  • Comments appear on the Journal’s website and are linked from the original article’s web page.
  • Authors are notified by email if their comments are posted.
  • The Journal reserves the right to edit comments for length and clarity.
  • No appeals will be considered.
  • Comments are not indexed in PubMed.

Specific requirements

  • Maximum length, 400 words
  • Entered as plain text or HTML
  • Author’s name and email address, to be posted with the comment
  • Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
  • Comments may not include figures
This field is required
This field is required
This field is required
This field is required
This field is required
This field is required

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts